US 12,257,217 B2
Compositions and methods for treating hyperphagia in prader-willi syndrome
Kee-Hong Kim, West Lafayette, IN (US); and Yuyan Zhu, Shenzhen (CN)
Assigned to Purdue Research Foundation, West Lafayette, IN (US)
Filed by Purdue Research Foundation, West Lafayette, IN (US)
Filed on Oct. 15, 2022, as Appl. No. 18/046,919.
Application 18/046,919 is a continuation of application No. 17/343,589, filed on Jun. 9, 2021, granted, now 11,872,198.
Application 17/343,589 is a continuation of application No. 16/461,597, granted, now 11,065,216, issued on Jul. 20, 2021, previously published as PCT/US2017/061893, filed on Nov. 16, 2017.
Claims priority of provisional application 62/422,722, filed on Nov. 16, 2016.
Prior Publication US 2023/0270702 A1, Aug. 31, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/18 (2006.01); A61K 31/167 (2006.01); A61P 3/04 (2006.01); A61P 3/06 (2006.01); A61P 3/10 (2006.01); C12N 15/113 (2010.01)
CPC A61K 31/18 (2013.01) [A61K 31/167 (2013.01); A61P 3/04 (2018.01); A61P 3/10 (2018.01); C12N 15/1137 (2013.01); A61P 3/06 (2018.01); C12N 2310/14 (2013.01); C12N 2310/531 (2013.01)] 18 Claims
OG exemplary drawing
 
1. A method for controlling abnormally increased appetite for consumption of food, the method comprising parenterally administering at least once in a month to an obese subject with Prader-Willi syndrome (PWS) a composition comprising an effective amount of avasimibe or a pharmacologically acceptable salt thereof that non-selectively inhibits in vivo both acyl-coenzyme A:cholesterol acyltransferase 1 (ACAT1) and acyl-coenzyme A:cholesterol acyltransferase 2 (ACAT2),
wherein the degree that the avasimibe or the pharmacologically acceptable salt thereof inhibits ACAT1 is less than the degree that the avasimibe inhibits ACAT2.